Jingru Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jingru Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Changyao Li
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publicationChongzhao You
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication- Guixia Xu
State Key Laboratory of Plant Diversity and Specialty Crops, Key Laboratory of Systematic and Evolutionary Botany, Institute of Botany, Chinese Academy of Sciences, Beijing, China
1 shared publication - H. Eric Xu
CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication - Jiangxia Zheng
College of Animal Science and Technology, China Agricultural University, Beijing 100193, China
1 shared publication Kai Wu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication
Latest Publications
- Open Access
- 17 June 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (26)
Structural basis for activation of somatostatin receptor 5 by cyclic neuropeptide agonists
Somatostatin receptor 5 (SSTR5) is an important G protein–coupled receptor and drug target for neuroendocrine tumors and pituitary disorders. This study presents two high-resolution cryogenicelectron microscope structures of the SSTR5-G i complexes bound to the cyclic neuropeptide agonists, cortistatin-17 (CST17) and octreotide, with resolutions of 2.7 Å and 2.9 Å, respectively. The structures reveal that binding of these peptides causes rearrangement of a “hydrophobic lock”, consisting of residues from transmembrane helices TM3 and TM6. This rearrangement triggers outward movement of TM6, enabling Gα i protein engagement and receptor activation. In addition to hydrophobic interactions, CST17 forms conserved polar contacts similar to somatostatin-14 binding to SSTR2, while further structural and functional analysis shows that extracellular loops differently recognize CST17 and octreotide. These insights elucidate agonist selectivity and activation mechanisms of SSTR5, providing valuable guidance for structure-based drug development targeting this therapeutically relevant receptor.
- 17 June 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (26)
Open AccessStructural basis for activation of somatostatin receptor 5 by cyclic neuropeptide agonists
Somatostatin receptor 5 (SSTR5) is an important G protein–coupled receptor and drug target for neuroendocrine tumors and pituitary disorders. This study presents two high-resolution cryogenicelectron microscope structures of the SSTR5-G i complexes bound to the cyclic neuropeptide agonists, cortistatin-17 (CST17) and octreotide, with resolutions of 2.7 Å and 2.9 Å, respectively. The structures reveal that binding of these peptides causes rearrangement of a “hydrophobic lock”, consisting of residues from transmembrane helices TM3 and TM6. This rearrangement triggers outward movement of TM6, enabling Gα i protein engagement and receptor activation. In addition to hydrophobic interactions, CST17 forms conserved polar contacts similar to somatostatin-14 binding to SSTR2, while further structural and functional analysis shows that extracellular loops differently recognize CST17 and octreotide. These insights elucidate agonist selectivity and activation mechanisms of SSTR5, providing valuable guidance for structure-based drug development targeting this therapeutically relevant receptor.
- 1 January 2008
- Published by S. Karger AG in Sexual Development
- Vol. 2 (6) , 309-315
Degree of Sex Differentiation of Genetic Female Chicken Treated with Different Doses of an Aromatase Inhibitor
Injection of an aromatase inhibitor before gonadal sex differentiation can induce female-to-male sex reversal in chicken, but a higher dose could reduce hatchability. In the present study, the dosage effect of Fadrozole, a nonsteroidal aromatase inhibitor, on gonadal differentiation was analyzed in sex-reversed genetic female chicken. There was no significant difference for the hatchability among low-dose (0.1, 0.3 and 0.5 mg) Fadrozole-injected groups and control groups (p > 0.05), but in high-dose groups (1.0 mg and 1.3 mg) the hatchability was significantly reduced (p < 0.05). Complete phenotypic sex reversal was observed in both high- and low- dose groups, with more than 90% of genetic females reversed into phenotypic male chicks. The degree of gonadal differentiation in 124 chicken at 30 weeks of age was classified into 5 categories according to the visual appearance and histological structure of the gonads. Category I and V were standard ovary and testis, respectively, while category II, III, and IV represented gonads of slightly, moderately, and highly sex-reversed females, respectively. Most gonads in low-dose groups were classified into category I, II, and III, while those in high-dose groups were mainly category IV. The serum testosterone levels in the 1.3 mg group were significantly higher and the estradiol levels lower than those in low-dose groups (p < 0.05). In conclusion, the range from 0.5 to 1.0 mg Fadrozole is a key interval for survival of chicken embryos. The gonadal differentiation in sex-reversed females at 30 weeks of age is highly dependent on the dose of Fadrozole injected prior to gonadal sex differentiation.
- 1 January 2008
- Published by S. Karger AG in Sexual Development
- Vol. 2 (6) , 309-315
Degree of Sex Differentiation of Genetic Female Chicken Treated with Different Doses of an Aromatase Inhibitor
Injection of an aromatase inhibitor before gonadal sex differentiation can induce female-to-male sex reversal in chicken, but a higher dose could reduce hatchability. In the present study, the dosage effect of Fadrozole, a nonsteroidal aromatase inhibitor, on gonadal differentiation was analyzed in sex-reversed genetic female chicken. There was no significant difference for the hatchability among low-dose (0.1, 0.3 and 0.5 mg) Fadrozole-injected groups and control groups (p > 0.05), but in high-dose groups (1.0 mg and 1.3 mg) the hatchability was significantly reduced (p < 0.05). Complete phenotypic sex reversal was observed in both high- and low- dose groups, with more than 90% of genetic females reversed into phenotypic male chicks. The degree of gonadal differentiation in 124 chicken at 30 weeks of age was classified into 5 categories according to the visual appearance and histological structure of the gonads. Category I and V were standard ovary and testis, respectively, while category II, III, and IV represented gonads of slightly, moderately, and highly sex-reversed females, respectively. Most gonads in low-dose groups were classified into category I, II, and III, while those in high-dose groups were mainly category IV. The serum testosterone levels in the 1.3 mg group were significantly higher and the estradiol levels lower than those in low-dose groups (p < 0.05). In conclusion, the range from 0.5 to 1.0 mg Fadrozole is a key interval for survival of chicken embryos. The gonadal differentiation in sex-reversed females at 30 weeks of age is highly dependent on the dose of Fadrozole injected prior to gonadal sex differentiation.